ARTICLE | Emerging Company Profile
New tac for modifying PAH
Targeting BMPRII signaling could give Selten first disease-modifying PAH therapy
August 10, 2015 7:00 AM UTC
Selten Pharma Inc. is developing a new formulation of the generic immunosuppressive drug tacrolimus that activates the BMPRII pathway and could prevent or even reverse the deleterious vascular remodeling seen with pulmonary arterial hypertension.
In PAH, increased smooth muscle cell proliferation and resistance to apoptosis in pulmonary vasculature results in narrowing and obstruction of the pulmonary arteries, hypertension, right ventricular hypertrophy and eventual death. ...